S. Dominguez

发表

Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13‐HEPAVIH cohort

M. Carrieri, B. Spire, P. Sogni, 2017, Addiction.

Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus

A. Samri, B. Autran, M. Guiguet, 2009, AIDS.

Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus‐1 mono‐infected patients on antiretroviral therapy

R. Tubiana, C. Katlama, F. Medja, 2009, Hepatology.

Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004.

J. Desenclos, S. Pol, L. Gambotti, 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.

D. Neau, P. Morlat, F. Dabis, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort

V. de Lédinghen, F. Dabis, T. Allègre, 2017, Journal of acquired immune deficiency syndromes.

Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs

F. Roudot-thoraval, S. Chevaliez, C. Hézode, 2020, Open forum infectious diseases.

Wildo Navegantes de Araújo, M. Ziol, V. Paradis, 2019, AIDS and Behavior.

A new 3 p 25 locus is associated with liver fibrosis progression in HIV / HCV co-infected patients

F. Dabis, J. Noirel, L. Abel, 2016 .

Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort).

F. Dabis, M. Carrieri, B. Spire, 2013, Addiction.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort

C. Katlama, D. Neau, P. Morlat, 2018, PLoS ONE.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort

C. Katlama, D. Neau, P. Morlat, 2018, PloS one.

Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients

V. Calvez, C. Katlama, B. Roquebert, 2006, Antimicrobial Agents and Chemotherapy.

HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)

M. Ziol, C. Delaugerre, C. Katlama, 2022, AIDS Research and Therapy.

Treatment of acute hepatitis C in human immunodeficiency virus–infected patients: The HEPAIG study

S. Pol, E. Delarocque-Astagneau, A. Gervais, 2010, Hepatology.

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study

V. de Lédinghen, D. Neau, P. Morlat, 2019, PloS one.

The Need for Data on Women Living with HIV in Europe

M. Johnson, A. Monforte, C. Miralles, 2013, Antiviral therapy.

Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.

R. Tubiana, C. Katlama, M. Guiguet, 2010, The Journal of antimicrobial chemotherapy.

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma

R. Tubiana, G. Peytavin, C. Poirot, 2008, AIDS.

Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients

C. Katlama, E. Caumes, G. Pialoux, 2006, AIDS.

Acute hepatitis C in HIV‐infected men who have sex with men

R. Tubiana, C. Katlama, E. Caumes, 2004, HIV medicine.

Treatment of Acute HCV Infection in HIV-Positive Patients: Experience from a Multicentre European Cohort

C. Katlama, M. Vogel, J. Rockstroh, 2010, Antiviral therapy.

Effect of antiretroviral drugs on the quality of semen

V. Calvez, R. Tubiana, G. Peytavin, 2011, Journal of medical virology.

Efficacy and Safety of Adefovir Dipivoxil plus Pegylated Interferon-α2a for the Treatment of Lamivudine-Resistant Hepatitis B virus Infection in HIV-Infected Patients

C. Katlama, T. Poynard, V. Thibault, 2008, Antiviral Therapy.

Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.

C. Katlama, T. Poynard, V. Thibault, 2008, Antiviral therapy.

Efficacy and safety of adefovir dipivoxil plus pegylated interferon-α 2 a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients

C. Katlama, T. Poynard, V. Thibault, 2022 .

Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis.

C. Katlama, P. Preziosi, T. Poynard, 2012, Journal of hepatology.

Ribavirin and abacavir drug interaction in HIV–HCV coinfected patients: fact or fiction?

J. Izopet, C. Solas, G. Peytavin, 2012, AIDS.

Foscarnet Salvage Therapy for Patients with Late-Stage HIV Disease and Multiple Drug Resistance

V. Calvez, C. Katlama, E. Caumes, 2005, Antiviral therapy.

Antiretroviral Therapy with a Twice-Daily Regimen Containing 400 Milligrams of Indinavir and 100 Milligrams of Ritonavir in Human Immunodeficiency Virus Type 1-Infected Women during Pregnancy

V. Calvez, R. Tubiana, C. Katlama, 2008, Antimicrobial Agents and Chemotherapy.

A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus‐coinfected patients

F. Dabis, J. Noirel, L. Abel, 2016, Hepatology.

Considerations for the Long-Term Management of Women Living with HIV in Europe

S. Dominguez, T. Branco, T. Haruperi, 2013, Antiviral therapy.

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.

D. Neau, P. Morlat, F. Dabis, 2017, Journal of hepatology.

Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).

M. Ziol, V. Paradis, C. Delaugerre, 2020, Journal of hepatology.

Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients

M. Carrieri, B. Spire, P. Sogni, 2018, PloS one.

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

Hassane Izzedine, J. Hulot, C. Goyenvalle, 2006, The Journal of infectious diseases.

Efficacy and safety of tenofovir double‐dose in treatment‐experienced HIV‐infected patients: The tenoplus study

V. Calvez, C. Katlama, G. Peytavin, 2007, Journal of medical virology.

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients

Vincent Calvez, Christine Katlama, V. Calvez, 2005, AIDS.

Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)

Roland Tubiana, Vincent Calvez, Christine Katlama, 2004, AIDS.

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

C. Charpentier, C. Delaugerre, J. Pawlotsky, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Virological and pharmacological factors associated with virological response to salvage therapy after an 8‐week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)

V. Calvez, C. Delaugerre, C. Katlama, 2005, Journal of medical virology.

Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy

V. Calvez, C. Delaugerre, C. Katlama, 2004, Antimicrobial Agents and Chemotherapy.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lack of TGF-β production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection.

A. Samri, B. Autran, M. Guiguet, 2012, Journal of hepatology.

Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.

V. Calvez, R. Tubiana, C. Katlama, 2004, Journal of acquired immune deficiency syndromes.

High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262)

N. Nagot, M. Lemoine, K. Lacombe, 2016, PloS one.

Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort

M. Ziol, C. Delaugerre, C. Katlama, 2020 .

Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.

C. Katlama, Y. Lévy, C. Solas, 2012, The Journal of antimicrobial chemotherapy.

Early Detection of Hepatitis C Virus Infection by Use of a New Combined Antigen-Antibody Detection Assay: Potential Use for High-Risk Individuals

R. Tubiana, C. Katlama, V. Thibault, 2006, Journal of Clinical Microbiology.